We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

MedXY Editorial Team•Aug 11, 2026•news
Cost-EffectivenessimmunotherapypembrolizumabPD-L1head and neck cancer

Highlight

  • KEYNOTE-689 trial showed perioperative pembrolizumab enhances event-free survival in locally advanced head and neck squamous cell carcinoma (HNSCC).
  • Cost-effectiveness analysis reveals pembrolizumab is economically viable only in patients with PD-L1 combined positive score (CPS) greater than 10.
  • Subgroup with CPS 1 to 10 exhibits marginal health gains at high incremental costs, limiting economic justification.
  • Biomarker-driven stratification can guide value-based use of immunotherapy in HNSCC treatment protocols.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaA phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.Sep 6, 2026Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple MyelomaMezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.Sep 3, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine Clinic
A surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancer
Sep 3, 2026
MDADI Composite Score Thresholds for Efficient Screening of Swallowing Impairment in Head and Neck Cancer PatientsThis study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.Aug 27, 2026
Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML EradicationThis study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.Aug 25, 2026